Zobrazeno 1 - 10 of 3 454 pro vyhledávání: '"Wellbrock, C."'
1
Akademický článek
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.
Autor: Redondo-Muñoz M; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain., Rodriguez-Baena FJ; Instituto de Neurociencias, CSIC-UMH, Sant Joan d'Alacant, Spain., Aldaz P; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain., Caballé-Mestres A; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Moncho-Amor V; Cellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.; CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), Madrid, Spain., Otaegi-Ugartemendia M; Cellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain., Carrasco-Garcia E; Cellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.; CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), Madrid, Spain., Olias-Arjona A; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain., Lasheras-Otero I; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain., Santamaria E; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain., Bocanegra A; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain.; Oncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Chocarro L; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain.; Oncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Grier A; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Dzieciatkowska M M; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Bigas C; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Martin J; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Urdiroz-Urricelqui U; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Marzo F; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain., Santamaria E; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain.; Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Kochan G; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain.; Oncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Escors D; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain.; Oncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Larrayoz IM; Biomarkers and Molecular Signaling Group, Center for Biomedical Research of La Rioja (CIBIR), Foundation Rioja Salud, Logroño, Spain.; Unidad Predepartamental de Enfermería, Universidad de La Rioja (UR), Logroño, Spain., Heyn H; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., D'Alessandro A; Oncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain., Attolini CS; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain., Matheu A; Cellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain., Wellbrock C; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.; Department of Health Sciences, Universidad Pública de Navarra (UPNA), Pamplona, Spain., Benitah SA; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. salvador.aznar-benitah@irbbarcelona.org.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain. salvador.aznar-benitah@irbbarcelona.org., Sanchez-Laorden B; Instituto de Neurociencias, CSIC-UMH, Sant Joan d'Alacant, Spain. berta.lopez@umh.es., Arozarena I; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain. iarozarm@navarra.es.; Health Research Institute of Navarre (IdiSNA), Pamplona, Spain. iarozarm@navarra.es.
Publikováno v: Nature metabolism [Nat Metab] 2023 Sep; Vol. 5 (9), pp. 1544-1562. Date of Electronic Publication: 2023 Aug 10.
Zobrazit plný text záznamu
2
Akademický článek
Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells.
Autor: Aldaz P; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain., Olias-Arjona A; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain., Lasheras-Otero I; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain., Ausin K; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.; Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain., Redondo-Muñoz M; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain., Wellbrock C; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.; Department of Health Sciences, Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain., Santamaria E; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.; Clinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain., Fernandez-Irigoyen J; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.; Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain., Arozarena I; Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Irunlarrea 3, 31008 Pamplona, Spain.; Health Research Institute of Navarre (IdiSNA), 31008 Pamplona, Spain.
Publikováno v: Pharmaceutics [Pharmaceutics] 2024 May 29; Vol. 16 (6). Date of Electronic Publication: 2024 May 29.
Zobrazit plný text záznamu
3
Akademický článek
Judging A Magazine by Its Cover – A Conceptual Framework to Understand Sales Through Content and Design Interaction.
Autor: Püchel, Lea, Wellbrock, C.-M.
Publikováno v: JMM: The International Journal on Media Management; Apr-Jun2022, Vol. 24 Issue 2, p87-116, 30p, 1 Diagram, 5 Charts
Zobrazit plný text záznamu
4
Akademický článek
The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma.
Autor: Lasheras-Otero I; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Feliu I; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Program in Solid Tumors, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain., Maillo A; Translational Bioinformatics Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain., Moreno H; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Program in Solid Tumors, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain., Redondo-Muñoz M; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Aldaz P; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Bocanegra A; Oncoimmunology Group, Navarrabiomed, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain., Olias-Arjona A; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Lecanda F; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Program in Solid Tumors, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Center for Biomedical Research Network on Cancer (CIBERONC), Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain., Fernandez-Irigoyen J; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Proteomics Platform, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain., Santamaria E; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Clinical Neuroproteomics Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain., Larrayoz IM; Biomarkers and Molecular Signaling Group, Center for Biomedical Research of La Rioja (CIBIR), Foundation Rioja Salud, Logroño, Spain; Pre-departmental Nursing Unit, University of La Rioja (UR), Logroño, La Rioja, Spain., Gomez-Cabrero D; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Translational Bioinformatics Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; Biological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia., Wellbrock C; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain., Vicent S; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Program in Solid Tumors, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; Center for Biomedical Research Network on Cancer (CIBERONC), Madrid, Spain., Arozarena I; Cancer Signaling Unit, Navarrabiomed, University Hospital of Navarra (HUN), Public University of Navarra (UPNA), Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. Electronic address: iarozarm@navarra.es.
Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2023 Feb; Vol. 143 (2), pp. 305-316.e5. Date of Electronic Publication: 2022 Sep 01.
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Phenotype plasticity as enabler of melanoma progression and therapy resistance.
Autor: Arozarena I; Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. Imanol.arozarena.martinicorena@navarra.es., Wellbrock C; Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Claudia.wellbrock@manchester.ac.uk.
Publikováno v: Nature reviews. Cancer [Nat Rev Cancer] 2019 Jul; Vol. 19 (7), pp. 377-391. Date of Electronic Publication: 2019 Jun 17.
Zobrazit plný text záznamu
10
Akademický článek
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached.
Autor: Wilcock DJ; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK., Badrock AP; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Wong CW; Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Owen R; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK., Guerin M; Program in Molecular Medicine, Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA., Southam AD; School of Biosciences, Edgbaston, University of Birmingham, Birmingham B15 2TT, UK; Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., Johnston H; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK., Telfer BA; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK., Fullwood P; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Watson J; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Ferguson H; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Ferguson J; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Lloyd GR; School of Biosciences, Edgbaston, University of Birmingham, Birmingham B15 2TT, UK; Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., Jankevics A; School of Biosciences, Edgbaston, University of Birmingham, Birmingham B15 2TT, UK; Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., Dunn WB; School of Biosciences, Edgbaston, University of Birmingham, Birmingham B15 2TT, UK; Phenome Centre Birmingham, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., Wellbrock C; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK., Lorigan P; Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK., Ceol C; Program in Molecular Medicine, Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA., Francavilla C; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK., Smith MP; Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK. Electronic address: michael.smith-8@manchester.ac.uk., Hurlstone AFL; Division of Infection Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Dover Street, Manchester M13 9PT, UK; Lydia Becker Institute of Immunology, The University of Manchester, Dover Street, Manchester M13 9PT, UK. Electronic address: adam.hurlstone@manchester.ac.uk.
Publikováno v: Cell reports [Cell Rep] 2022 Jun 21; Vol. 39 (12), pp. 110995.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje